Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 114 (4), 559-65

Binding of Antidepressants to Human Brain Receptors: Focus on Newer Generation Compounds

Affiliations

Binding of Antidepressants to Human Brain Receptors: Focus on Newer Generation Compounds

B Cusack et al. Psychopharmacology (Berl).

Abstract

Using radioligand binding assays and post-mortem normal human brain tissue, we obtained equilibrium dissociation constants (Kds) for 17 antidepressants and two of their metabolites at histamine H1, muscarinic, alpha 1-adrenergic, alpha 2-adrenergic, dopamine D2, serotonin 5-HT1A, and serotonin 5-HT2 receptors. Several newer antidepressants were compared with older drugs. In addition, we studied some antimuscarinic, antiparkinson, antihistamine, and neuroleptic compounds at some of these receptors. For the antidepressants, classical tricyclic antidepressants were the most potent drugs at five of the seven receptors (all but alpha 2-adrenergic and 5-HT1A receptors). The chlorophenylpiperazine derivative antidepressants (etoperidone, nefazodone, trazodone) were the most potent antidepressants at alpha 2-adrenergic and 5-HT1A receptors. Of ten antihistamines tested, none was more potent than doxepin at histamine H1 receptors. At muscarinic receptors antidepressants and antihistamines had a range of potencies, which were mostly weaker than those for antimuscarinics. From the in vitro data, we expect adinazolam, bupropion, fluoxetine, sertraline, tomoxetine, and venlafaxine not to block any of these five receptors in vivo. An antidepressant's potency for blocking a specific receptor is predictive of certain side effects and drug-drug interactions. These studies can provide guidelines for the clinician in the choice of antidepressant.

Similar articles

See all similar articles

Cited by 43 PubMed Central articles

See all "Cited by" articles

References

    1. Biochem Pharmacol. 1993 Jun 9;45(11):2352-4 - PubMed
    1. J Pharmacol Exp Ther. 1984 Jul;230(1):94-102 - PubMed
    1. Eur J Pharmacol. 1987 Nov 10;143(2):279-82 - PubMed
    1. Mol Pharmacol. 1986 Apr;29(4):321-30 - PubMed
    1. Nature. 1983 Sep 8-14;305(5930):140-2 - PubMed

Publication types

MeSH terms

LinkOut - more resources

Feedback